Proprietary high-yield CHO cells. AI-assisted antibody sequence design. CRISPR precision gene editing. From antibody sequence to stable CHO cell line in weeks, not months.
CHO cell line development is the process of engineering Chinese Hamster Ovary (CHO) cells — the mammalian expression system most widely used across the biopharmaceutical and IVD industries — to express a target protein such as a recombinant antibody. A stable CHO cell line results when the antibody gene is permanently integrated into the CHO cell genome, producing a clonal cell line that reliably expresses the same antibody, batch after batch, without re-transfection. This is distinct from transient expression, where the gene is not integrated and expression declines after a few days.
Sekbio's stable CHO cell line development program is built on three integrated technologies:
For IVD manufacturers and biopharma developers, choosing an experienced CHO cell line development partner reduces the risk of failed expression, shortens the path from antibody sequence to a production-ready stable CHO cell line, and helps ensure the lot-to-lot consistency required for diagnostic and therapeutic manufacturing.
Speed and consistency in CHO cell line development come from three integrated technologies working together — not from cutting corners.
Sekbio's in-house CHO cell line delivers up to 2.4 g/L peak protein yield with 7-day expression turnaround — the same platform behind 800+ successful CHO cell antibody production projects.
Machine learning-driven construct optimization evaluates codon usage, signal peptides, and vector architecture — reducing design-test-redesign cycles before CHO cell line development begins.
CRISPR precision gene-editing technology improves target-gene insertion efficiency into the CHO cell genome, increasing correctly-integrated, high-expressing clones and accelerating stable CHO cell line development.
Every CHO cell antibody production batch is characterized to full analytical standards and is scalable from milligram screening to 100+ L manufacturing.
See full specifications on the CHO Expression Platform, or read more on the CHO Cell Expression System and CHO vs HEK293 for IVD Antibody Production.
Sekbio's CHO stable cell line development has been applied to construct stable CHO cell lines for a range of diagnostic and research targets, including:
Stable CHO cell line development supporting cardiovascular and metabolic research and diagnostic antibody development.
Stable CHO cell line development for HIV diagnostic antibody development.
Stable CHO cell line development for infectious disease diagnostic antibody development.
These targets are representative of the range of antibodies supported by Sekbio's CHO cell antibody production platform, alongside monoclonal antibodies (IgG, IgM, IgA), bispecifics, Fab/scFv/VHH fragments, Fc fusions, and recombinant antigens. Browse additional project examples in Sekbio Case Studies.
CHO cell antibody production at Sekbio is delivered as an integrated service spanning transient expression verification, stable CHO cell line development, scale-up CHO cell antibody production, and CHO cell culture media supply.
From antibody sequence to validated expression — if your antibody shows no functional activity, we charge nothing. 800+ successful projects. Zero financial risk.
Sekbio's proprietary expression technology shortens the typical 3–8 month stable cell line development process to 3–5 weeks.
Sekbio antibodies are manufactured at industrial scale — large batch sizes, tight lot-to-lot CV, and full ISO 13485-certified traceability. Validate once, produce with confidence.
Validate antibody expression and functional activity before committing to stable cell line construction.
Construct a stable CHO cell line of recombinant antibody for consistent, long-term production.
Scale-up CHO cell antibody production from milligram to 100+ L, with full QC and batch documentation.
Ready-to-use CHO cell culture media and feed media for in-house CHO cell antibody production.
Sekbio supplies ready-to-use CHO cell culture media and feed media formulated for high-density CHO cell antibody production — available for in-house use or as part of a full CHO cell line development project.
| Product Name | Cat. No. | Form | Volume | Storage Condition | Shelf Life |
|---|---|---|---|---|---|
| Medium A CHO Medium | SekMAC01-1000 | Liquid | 1000 mL | 2–8°C, protected from light | 12 months |
| Feed Medium FA | SekS01-1000 | Liquid | 1000 mL | 2–8°C, protected from light | 12 months |
| Feed Medium FB | SekS02-1000 | Liquid | 1000 mL | 2–8°C, protected from light | 12 months |
| Feed Medium FB | SekS02-100 | Liquid | 100 mL | 2–8°C, protected from light | 12 months |
Answers to the questions clients most often ask about CHO cell line development.
CHO cell line development is the process of engineering Chinese Hamster Ovary (CHO) cells to express a target protein — most commonly a recombinant antibody — at high yield and consistent quality. A stable CHO cell line integrates the antibody gene permanently into the CHO cell genome, so the resulting clonal cell line keeps expressing the same antibody across generations and production batches. Sekbio's CHO stable cell line development combines a proprietary high-yield CHO cell line, AI-assisted antibody sequence design, and CRISPR precision gene editing.
Sekbio uses its own in-house, high-productivity CHO cells — the same platform behind its 7-day transient expression turnaround and peak yields of up to 2.4 g/L. This proprietary CHO cell line has supported 800+ successful expression projects and is the foundation for both transient expression verification and stable CHO cell line development.
Sekbio applies machine learning-driven construct optimization to antibody sequence design before expression begins — evaluating codon usage, signal peptide selection, and vector architecture. This reduces the number of design-test-redesign cycles typically needed to reach an expression-ready construct for CHO cell antibody production.
Sekbio applies CRISPR precision gene-editing technology to improve target-gene insertion efficiency into the CHO cell genome. This increases the proportion of clones carrying a correctly integrated, high-expressing copy of the antibody gene, reducing the number of clones that must be screened and accelerating CHO stable cell line development.
Once a candidate antibody passes bioreactivity evaluation, Sekbio's proprietary expression technology shortens stable CHO cell line development from the industry-typical 3–8 months to approximately 3–5 weeks — covering cell line construction, high-volume production, purification, and evaluation.
CHO cell antibody production at Sekbio follows three stages. Stage 1 (2–3 weeks): transient expression and purification of 1–8 mg antibody from a DNA sequence, with an expression-difficulty assessment. Stage 2 (1–2 weeks): bioreactivity evaluation by ELISA, LFT, or CLIA against the original antibody to confirm readiness, yielding at least 2 mg purified antibody. Stage 3 (3–5 weeks): stable CHO cell line development from the antibody DNA plasmid, producing 300–500 mg of antibody plus purity and bioreactivity results and the stable cell line itself.
Representative targets with successfully constructed stable CHO cell lines include PCSK9, HIV p24, and COVID-19 (SARS-CoV-2)-related antigens, in addition to a broad range of monoclonal antibodies, bispecifics, Fab/scFv/VHH fragments, Fc fusions, and recombinant antigens supported by the CHO cell platform.
Start your CHO cell antibody production project today. Proprietary CHO cells, AI-assisted design, CRISPR precision gene editing.
Our team responds within 24 hours.